F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
Left (3)
FDA approves landmark pancreatic cancer drug that's shown to improve survival
U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer, by blocking a protein that fuels tumor growth in the vast majority of cases.
Aug 27, 2026
FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
In trials, Revolution Medicines’ daraxonrasib nearly doubled average survival times for one of the deadliest cancers.
Aug 26, 2026
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
Aug 26, 2026
Center (2)
US drug agency approves breakthrough treatment for pancreatic cancer
Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers.
Aug 26, 2026
FDA approves groundbreaking new pancreatic cancer drug
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque. It was approved for patients who already tried…
Aug 26, 2026
Right (3)
FDA approves breakthrough pancreatic cancer drug proven to extend survival
The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success with chemotherapy. Doctors have sung the praises of the drug, and […]
Aug 26, 2026
FDA Approves Pancreatic Cancer Drug That Nearly Doubled Survival In Trial
The U.S. Food and Drug Administration (FDA) on Wednesday approved a groundbreaking new treatment for advanced pancreatic cancer that nearly doubled median survival in a clinical trial, marking what experts are calling one of the biggest advances against the deadly disease in decades. The drug, daraxonrasib, which will be sold under the brand name Rasonque, ...
Aug 26, 2026
FDA approves ‘life-altering’ pancreatic cancer drug that nearly doubles life expectancy
Daraxonrasib made headlines earlier this year when former US Sen. Ben Sasse, R-Neb., shared details about his experience with the drug — which left his skin bloody and “bubbling” but is giving him more time with his family.
Aug 26, 2026